Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by subaru1ion Dec 23, 2023 12:09pm
194 Views
Post# 35799141

RE:RE:RE:Shareholders

RE:RE:RE:Shareholders Agree, reading between the lines is not silent but rather screaming in your face.  Golden parachutes issued at $.06 and negative eps?  On the surface it makes no sense at all until you bring the bigger picture into clearer focus and hence a very loud and bullish indicator.   Brazilian news is according to what we know so far is generic based but we have no idea what the new drug application is about except that it is a new drug that currently does not exist.   I think it's a new cancer drug, a natural extension of scientific evidence in the field of oncology involving cannabinoids.   All of the early presentations be it by Yolav Goladi or Dedi Meri had as their focal point cancer killed by cannabinoid compounds and extend the scientific work and evidence of that past into the present and hence my logical process saying the NDA is for cancer.   

If, Then, logic.   If the NDA is for a new cancer drug then it would substantiate the request by the NIH in writing to the DEA to remove it from Schedule 1 to Schedule 3 in conjunction with Biden being briefed and now granting pardons and admitting their prior approach was wrong. 

For me those pieces connect very clearly and who got a tid bit of that info when volume surged to 1.66 million shares....information tends to be 'leaky' at best. 


<< Previous
Bullboard Posts
Next >>